Holen Sie sich die Stockscreener-App
59.65
3.48%
-2.15
Vorhandelsmarkt:
58.90
-0.75
-1.26%
Schlusskurs vom Vortag:
$61.80
Offen:
$60
24-Stunden-Volumen:
642.44K
Relative Volume:
0.54
Marktkapitalisierung:
$2.56B
Einnahmen:
$147.17M
Nettoeinkommen (Verlust:
$-408.35M
KGV:
-5.336
EPS:
-11.1787
Netto-Cashflow:
$-299.92M
1W Leistung:
-3.23%
1M Leistung:
+19.80%
6M Leistung:
-25.09%
1J Leistung:
+52.99%
1-Tages-Spanne:
$58.37
$61.76
1-Wochen-Bereich:
$58.37
$63.51
52-Wochen-Spanne:
$29.95
$118.84
Grail Inc Stock (GRAL) Company Profile
Firmenname
Grail Inc
Sektor
Branche
Telefon
(833) 694-2553
Adresse
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
59.65 | 2.65B | 147.17M | -408.35M | -299.92M | -11.18 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Mizuho | Neutral |
| 2026-03-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-19 | Eingeleitet | TD Cowen | Hold |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-10-17 | Eingeleitet | Guggenheim | Neutral |
Alle ansehen
Grail Inc Aktie (GRAL) Neueste Nachrichten
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead - MarketBeat
GRAIL partners with Epic to broaden Galleri test access across US - MSN
Grail Inc. Earnings Call Highlights Growth Amid Risks - TipRanks
Baker Bros. reports 4.03M-share stake in GRAIL (NASDAQ: GRAL) - Stock Titan
How GRAIL’s Narrowed Q1 2026 Loss Profile Will Impact GRAIL (GRAL) Investors - simplywall.st
GRAIL, Inc. $GRAL Stock Holdings Lifted by WIM INVESTMENT MANAGEMENT Ltd - MarketBeat
The Cancer Test That Wall Street Is Betting On - WSJ
Grail (GRAL) Q1 2026 Earnings Transcript - AOL.com
Number of shareholders of GRAIL, Inc. – NASDAQ:GRAL - TradingView
Archaeopteryx | The Holy Grail of Fossils at the Field Museum - Britannica
GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations - MSN
Farallon (GRAL) reports 2.68M shares and 571K warrants; 9.99% cap - Stock Titan
GRAIL, Inc. Hits Day High with 15.35% Surge in Strong Intraday Performance - Markets Mojo
Here's Why Grail Shares Popped Higher This Week - The Motley Fool
GRAIL (NASDAQ:GRAL) Upgraded at Wall Street Zen - MarketBeat
Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter Results - simplywall.st
Grail | 10-Q: Q1 2026 Earnings Report - Moomoo
How The GRAIL (GRAL) Narrative Is Shifting After NHS Galleri Results And Reimbursement Questions - Yahoo Finance
GRAIL : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
[10-Q] GRAIL, Inc. Quarterly Earnings Report - Stock Titan
GRAIL to Present New Data on Multi-Cancer Early Detection Test - Clinical Lab Products
Technical Reactions to GRAL Trends in Macro Strategies - Stock Traders Daily
CCORF Maintains Grail(GRAL.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Grail Is Maintained at Neutral by Piper Sandler - Moomoo
Piper Sandler Maintains Grail(GRAL.US) With Hold Rating, Raises Target Price to $56 - Moomoo
GRAIL (NASDAQ:GRAL) Is In A Good Position To Deliver On Growth Plans - Moomoo
What GRAIL (GRAL)'s Narrowed Q1 Loss And Revenue Growth Means For Shareholders - simplywall.st
Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69 - TipRanks
GRAIL Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Grail Q1 2026 revenue beats forecast, stock rises By Investing.com - Investing.com South Africa
Grail Plans to Integrate Galleri Test Into Epic Electronic Health Record Platform to Expand Access Nationwide >GRAL - Moomoo
Grail 1Q Loss $93.2M >GRAL - Moomoo
Earnings call transcript: Grail Q1 2026 revenue beats forecast, stock rises - Investing.com
Grail Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GRAIL INC (NASDAQ:GRAL) Stock Falls After-Hours Despite Q1 Beat and Galleri Test Volume Surge - ChartMill
GRAIL Inc. (GRAL) stock falls on Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (GRAL) GRAIL, Inc. Reports Q1 Revenue $40.8M, vs. FactSet Est of $39.2M - marketscreener.com
Grail 1Q Loss/Shr $2.29 >GRAL - Moomoo
Earnings Flash (GRAL) GRAIL, Inc. Reports Q1 Revenue $40.8M, Vs. FactSet Est of $39.2M - Moomoo
GRAIL (NASDAQ: GRAL) posts 28% Q1 growth and advances Galleri PMA - Stock Titan
GRAIL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
GRAIL (GRAL) Price Target Decreased by 18.81% to 69.07 - MSN
Grail earnings ahead as investors weigh trial results, FDA path By Investing.com - Investing.com UK
GRAIL, Inc. Hits Day High with Strong 7.44% Intraday Surge - Markets Mojo
GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - ChartMill
GRAIL to Present at the BofA Securities 2026 Health Care Conference - ChartMill
Why Grail Stock Is Breaking Out Today - TipRanks
GRAIL announces leadership transition - MSN
GRAIL executives head to Las Vegas conference, webcast starts May 12 - Stock Titan
GRAIL (NASDAQ: GRAL) outlines CEO transition, director elections in 2026 proxy - Stock Titan
GRAIL (GRAL) to Release Quarterly Earnings on Tuesday - MarketBeat
Finanzdaten der Grail Inc-Aktie (GRAL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):